x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Pharma and BioTech Daily

Pharma and BioTech News

Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.Produced by OWITH.ai, a boutique AI & data studio. Sponsor the show: https://sponsor.owith.ai

news tech news

All Episodes

5:34

Strategic Acquisitions and AI Revolutionize Pharma...

Pharma and BioTech Daily ·

2025/10/23

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal changes and innovations shaping the industry landscape.Let's begin with a significant acquisition that is resonating across the sector. Alkermes has strategically acquired Avadel Pharmaceuticals for a noteworthy $2.1 billion. This acquisition is primarily aimed at Avadel's long-acting narcolepsy drug, Lumryz. This mov...

en-us

6:13

Industry Shifts: Novo Nordisk's Revamp & ADC...

Pharma and BioTech Daily ·

2025/10/22

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant shifts occurring in these industries, touching on strategic restructuring, regulatory milestones, and groundbreaking scientific advancements that are shaping the future of drug development and patient care.Let's begin with a major corporate shakeup at Novo Nordisk. The company has announced a significant lead...

en-us

6:26

Transformative Advances in Precision Oncology and ADCs

Pharma and BioTech Daily ·

2025/10/21

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody-drug conjugate, Datroway, demonstrated superior efficacy compared to Gilead's Trod...

en-us

5:51

Transformative Oncology Breakthroughs and Regulatory...

Pharma and BioTech Daily ·

2025/10/20

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into a series of remarkable advancements and strategic movements shaping the landscape of healthcare. Let's start with a recent spotlight on the European Society for Medical Oncology Congress 2025, where key clinical trial outcomes have emerged, potentially reshaping future treatment protocols.AstraZeneca made waves with its Phase 3 trial resu...

en-us

30:10

Week in review October 18th 2025

Pharma and BioTech Daily ·

2025/10/18

This Week in Review covers episodes from October 14 to October 17, featuring major developments in the pharmaceutical and biotech industries. Episodes included: Biotech Breakthroughs: Partnerships, AI, and Clinical TriumphsPharma Breakthroughs: Advancing Cancer, Diabetes, and HIV CareNavigating Regulatory Shifts and Strategic Mergers in BiotechRevolutionizing Care: Key Biotech Breakthroughs and TrendsKey topics covered: Strategic acquisitions and partnershipsRegulatory updates and FDA approva...

en-us

9:40

Biotech Breakthroughs: Partnerships, AI, and Clinical...

Pharma and BioTech Daily ·

2025/10/17

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of fascinating updates that underscore a period of significant scientific advancement, strategic partnerships, and regulatory developments in the industry.Starting with Dianthus Therapeutics, which has taken a bold step by investing up to $1 billion to license a bifunctional fusion protein from Nanjing Leads Biolabs. This prote...

en-us

5:26

Pharma Breakthroughs: Advancing Cancer, Diabetes, and...

Pharma and BioTech Daily ·

2025/10/16

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of major advancements and strategic moves that are shaping the future of healthcare.A significant development comes from AstraZeneca, which has committed a substantial $445 million investment to bolster production at its Texas facility for Lokelma, a treatment designed for hyperkalemia. Hyperkalemia is a condition characterized ...

en-us

6:46

Navigating Regulatory Shifts and Strategic Mergers in...

Pharma and BioTech Daily ·

2025/10/15

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the rapidly evolving landscape of the pharmaceutical and biotech sectors, where regulatory updates, strategic mergers, and scientific breakthroughs are continually reshaping the industry.Starting with Novo Nordisk's recent challenges, their newly acquired manufacturing facility in Indiana has been flagged by the FDA with an "Official Action Ind...

en-us

7:34

Revolutionizing Care: Key Biotech Breakthroughs and...

Pharma and BioTech Daily ·

2025/10/14

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest news shaping this dynamic industry.Bristol Myers Squibb recently made headlines with their acquisition of Orbital Therapeutics for a remarkable $1.5 billion. This strategic move is aimed at enhancing their in vivo cell therapy capabilities, particularly in treating autoimmune disorders. In vivo cell therapy is a pioneering approach tha...

en-us

2:08

Pharma and Biotech Daily: Keeping You Informed on FDA...

Pharma and BioTech Daily ·

2025/10/13

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ##FDA Approves New Cancer TreatmentThe FDA has approved a new cancer treatment that has shown promising results in clinical trials. This treatment is expected to provide a new option for patients who have not responded well to traditional therapies. ##Drug Company Announces Major Breakthrough in Alzheimer's ResearchA drug company has announced a major breakthro...

en-us

4:30

Week in Review - October 10, 2025

Pharma and BioTech Daily ·

2025/10/12

his Week in Review covers 5 episodes from October 06 to October 10, featuring major developments in the pharmaceutical and biotech industries. Episodes included: 1. Pharma and Biotech Daily: Novo's Acquisition, FDA Breakthroughs, and Industry Updates 2. Pharma and Biotech Daily: Top Stories in the Industry from Zenas to Lilly 3. Pharma and Biotech Daily: Tariff Impact, Promising Trials, and Industry Leaders 4. Pharma and Biotech Daily: The Latest in Cell and Gene Therapy, M&A Activity, an...

en-us

0:51

Pharma and Biotech Daily: Novo's Acquisition, FDA...

Pharma and BioTech Daily ·

2025/10/10

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.Novo has recently completed the acquisition of Akero in a deal valued at up to $5.2 billion. This acquisition adds Akero's efruxifermin to Novo's already impressive portfolio. The FDA breakthrough drugs continue to show promise, with nearly three quarters of designated drugs being approved, especially in the rare disease and cancer categories.In other news, ther...

en-us

1:46

Pharma and Biotech Daily: Top Stories in the Industry...

Pharma and BioTech Daily ·

2025/10/09

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Zenas has made a $2 billion bet on autoimmune diseases with Chinese firm InnoCare, focusing on the development of orelabrutinib for multiple sclerosis. Former FDA director Peter Marks has joined Eli Lilly, marking the company's continued push in China. Sanofi's advancements in radiopharma, Boehringer Ingelheim's breakthrough in idiopathic pulmonary fibrosis, and Taked...

en-us

1:30

Pharma and Biotech Daily: Tariff Impact, Promising...

Pharma and BioTech Daily ·

2025/10/08

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A new survey from CRB shows that most life sciences companies, particularly smaller biotechs, are not planning new investments in response to tariffs. The majority of manufacturing initiatives in the U.S. made in response to tariffs are coming from big pharma companies. Sky Bioscience's CB1 inhibitor, Nimacimab, showed promising weight-loss results when combined wit...

en-us

1:49

Pharma and Biotech Daily: The Latest in Cell and Gene...

Pharma and BioTech Daily ·

2025/10/07

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Chiesi has entered a $2.1 billion collaboration with Arbor to develop a gene therapy for primary hyperoxaluria type 1. AstraZeneca continues to invest in AI partnerships, FDA lifts clinical hold on Neurizon's ALS drug, and the cell and gene therapy field faces challenges and opportunities at the Meeting on the Mesa event. CDC adopts ACIP recommendations, FDA's manufac...

en-us

0:51

The Essential Updates in Pharma and Biotech: Your...

Pharma and BioTech Daily ·

2025/10/06

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Former NIAID director Jeanne Marrazzo was fired after filing a whistleblower report, alleging retaliation. The FDA's new cell and gene therapy guidances have been well-received for streamlining therapies. In other news, CMS has finalized stronger protections for orphan drugs, and Amgen's Repatha has shown positive results in preventing heart disease. Lotte Biologics ...

en-us

0:56

Pharma and Biotech Daily: Top Stories from the Industry

Pharma and BioTech Daily ·

2025/10/03

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. President Trump has once again delayed the imposition of 100% tariffs on pharmaceuticals, with preparations now set to begin on October 1. Halozyme's acquisition of Elektrofi for $900 million has brought two major pharmaceutical partners together, while Takeda is exiting the cell therapy sector and laying off 137 employees. Roche's $3.5 billion takeover of 89bio wa...

en-us

1:48

Pharma and Biotech Daily: Navigating Industry Shifts...

Pharma and BioTech Daily ·

2025/10/02

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry...

en-us

1:12

Pharma and Biotech Daily: Metsera's Mid-Stage...

Pharma and BioTech Daily ·

2025/10/01

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's mid-stage obesity drug, met-097i, has shown "very encouraging" efficacy, supporting Pfizer's proposed $4.9 billion buyout of the company. The drug's performance is seen as positive by BMO Capital Markets. In other news, drug manufacturers are increasingly utilizing artificial intelligence throughout the drug production process, moving from using AI for sp...

en-us

1:52

Pharma and Biotech Daily: Genmab Acquires Merus, GSK...

Pharma and BioTech Daily ·

2025/09/30

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next yea...

en-us

434 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS News

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci